A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.

摘要: AbstractDose intensity has been demonstrated to be one determinant for treatment efficacy in younger adults with high-risk (relapsed and refractory) acute myelogenous leukemia. Between 2000 2006, 56 patients entered the EMA study received timed sequential reinduction chemotherapy. From 2004, chemotherapy was also followed by subcutaneous dose of pegfilgrastim. Thirty-six reached a complete remission, while nine obtained partial remission. Median time granulocyte platelet recovery 34 38 days respectively. The major non-hematologic toxicities were severe infections but despite this 23 remitters could proceed their post-remission treatment, although 13 did not because toxicity or early relapse. median overall survival 9·3 months. regimen is highly effective response rate 64% low death rate. period critical neutropenia relatively short both phases supportive use pegfilgrastim...